LifeMD, Inc. Changes Certifying Accountant

TL;DR

LifeMD swapped accountants, filing an 8-K on 8/21/25 regarding the change effective 8/15/25.

AI Summary

LifeMD, Inc. filed an 8-K on August 21, 2025, reporting a change in its certifying accountant as of August 15, 2025. The company previously operated under the names Conversion Labs, Inc. and Immudyne, Inc. before changing its name to LifeMD, Inc. on June 22, 2018.

Why It Matters

A change in a company's auditor can sometimes signal underlying financial concerns or a desire for a fresh perspective on financial reporting.

Risk Assessment

Risk Level: low — This filing solely reports a change in the company's independent auditor, which is a routine administrative event.

Key Players & Entities

• LifeMD, Inc. (company) — Registrant
• August 15, 2025 (date) — Date of earliest event reported
• August 21, 2025 (date) — Date of report
• Conversion Labs, Inc. (company) — Former company name
• Immudyne, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share LFMD The Nasdaq Global Ma
• $0.0001 — ve Perpetual Preferred Stock, par value $0.0001 per share LFMDP The Nasdaq Global M

Filing Documents

• form8-k.htm (8-K) — 47KB
• ex16-1.htm (EX-16.1) — 5KB
• 0001493152-25-012214.txt ( ) — 259KB
• lfmd-20250815.xsd (EX-101.SCH) — 4KB
• lfmd-20250815_def.xml (EX-101.DEF) — 26KB
• lfmd-20250815_lab.xml (EX-101.LAB) — 36KB
• lfmd-20250815_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

financial statements

financial statements. From the period April 24, 2025 through the date of CBIZ CPAs' dismissal, there were no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended ("Regulation S-K"), and the related instructions thereto, with CBIZ CPAs on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of CBIZ CPAs, would have caused CBIZ CPAs to make reference to the subject matter of the disagreements in connection with a report, if CBIZ CPAs had issued such a report. From the period April 24, 2025 through the date of CBIZ CPAs' dismissal, there were no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K except for the following material weaknesses in our internal control over financial reporting related to: (i) our information technology general controls ("ITGCs"), particularly in the areas of user access and change management within our information systems and review of key third-party service provider Systems and Organizational Controls ("SOC") reports and (ii) business process controls related to Information Produced by the Entity ("IPE") and system generated IPE and insufficient evidence of formal review and approval procedures of key information utilized in the performance of the control. The Company has provided CBIZ CPAs with a copy of the foregoing disclosures and has requested that CBIZ CPAs furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of such letter, which is dated August 21 2025, is filed as Exhibit 16.1 to this Form 8-K. Appointment of Independent Registered Public Accounting Firm On August 18, 2025, the Company, with the approval of the Audit Committee of the Company's Board of Directors, appointed PricewaterhouseCoopers

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIFEMD, INC. Dated: August 21, 2025 By: /s/ Maria Stan Maria Stan Chief Accounting Officer

View Full Filing

View this 8-K filing on SEC EDGAR